Deepa R Camenga1, Hector A Colon-Rivera2,3, Srinivas B Muvvala4. 1. Department of Emergency Medicine, Yale School of Medicine, New Haven, Connecticut. 2. Department of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania. 3. Department of Behavioral Health, Asociación Puertorriqueños en Marcha, Inc. (APM), Philadelphia, Pennsylvania. 4. Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut.
Abstract
OBJECTIVE: Methadone, buprenorphine, and naltrexone are evidence-based treatments for opioid use disorder (OUD). A large body of evidence supports their effectiveness in adults with OUD. However, few studies have tested their efficacy in adolescents. This study summarizes the clinical benefits and risks of three medications for the treatment of OUD in adolescents. METHOD: We review and synthesize the published evidence about the efficacy and potential risks (including safety concerns) associated with methadone, buprenorphine, or naltrexone for the treatment of OUD in adolescents and compare their benefits and risks with that of no treatment or treatment without medications. We also discuss adolescent-specific treatment needs and strategies to overcome potential challenges in prescribing medications for adolescents with OUD. RESULTS: Methadone appears to be effective in promoting treatment retention among adolescents with heroin use disorder. Data from three randomized controlled trials suggest that buprenorphine treatment improves the likelihood of opioid abstinence and treatment retention. Although these medications have a potential risk of overdose when misused or used illegally, evidence suggests this risk is much lower for buprenorphine than methadone. Emerging data also suggest that naltrexone is a safe and feasible option for adolescents. Vast evidence demonstrates that the risks of untreated OUD far outweigh the risks of any of the previously discussed medications. CONCLUSIONS: Little published evidence specifically examines the efficacy and safety of using medications for OUD in adolescents, and more research is needed. It is essential for healthcare professionals to determine whether their adolescent patients may benefit from medications for the treatment of OUD.
OBJECTIVE:Methadone, buprenorphine, and naltrexone are evidence-based treatments for opioid use disorder (OUD). A large body of evidence supports their effectiveness in adults with OUD. However, few studies have tested their efficacy in adolescents. This study summarizes the clinical benefits and risks of three medications for the treatment of OUD in adolescents. METHOD: We review and synthesize the published evidence about the efficacy and potential risks (including safety concerns) associated with methadone, buprenorphine, or naltrexone for the treatment of OUD in adolescents and compare their benefits and risks with that of no treatment or treatment without medications. We also discuss adolescent-specific treatment needs and strategies to overcome potential challenges in prescribing medications for adolescents with OUD. RESULTS:Methadone appears to be effective in promoting treatment retention among adolescents with heroin use disorder. Data from three randomized controlled trials suggest that buprenorphine treatment improves the likelihood of opioid abstinence and treatment retention. Although these medications have a potential risk of overdose when misused or used illegally, evidence suggests this risk is much lower for buprenorphine than methadone. Emerging data also suggest that naltrexone is a safe and feasible option for adolescents. Vast evidence demonstrates that the risks of untreated OUD far outweigh the risks of any of the previously discussed medications. CONCLUSIONS: Little published evidence specifically examines the efficacy and safety of using medications for OUD in adolescents, and more research is needed. It is essential for healthcare professionals to determine whether their adolescent patients may benefit from medications for the treatment of OUD.
Authors: Tiffany Champagne-Langabeer; Marylou Cardenas-Turanzas; Irma T Ugalde; Christine Bakos-Block; Angela L Stotts; Lisa Cleveland; Steven Shoptaw; James R Langabeer Journal: Children (Basel) Date: 2022-04-07
Authors: Carrie M Mintz; Ned J Presnall; John M Sahrmann; Jacob T Borodovsky; Paul E A Glaser; Laura J Bierut; Richard A Grucza Journal: Drug Alcohol Depend Date: 2020-06-18 Impact factor: 4.492
Authors: Sara J Becker; Kelli Scott; Sarah A Helseth; Kristin J Danko; Ethan M Balk; Ian J Saldanha; Gaelen P Adam; Dale W Steele Journal: J Subst Abuse Treat Date: 2021-05-29
Authors: Gabriela Garcia-Vassallo; Ellen Lockard Edens; Brady Heward; Marc A Auerbach; Ambrose H Wong; Deepa Camenga Journal: MedEdPORTAL Date: 2021-04-20